Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American

 Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology
 Pivotal Phase 3 Data Being Presented at the American College of Rheumatology
                                Annual Meeting

PR Newswire

NEW BRUNSWICK, N.J., Nov. 2, 2012

NEW BRUNSWICK, N.J., Nov. 2, 2012 /PRNewswire/ --Janssen and Johnson &
Johnson (NYSE: JNJ)will provide a pre-recorded webcast for investors and
other interested parties on Saturday, November 10, at approximately 5:00 p.m.,
Eastern Time, to coincide with the American College of Rheumatology (ACR)
Annual Meeting  being held in Washington, D.C.

The presentation will highlight new, pivotal Phase 3 study findings,
including;

  oIntravenous Golimumab Inhibits Radiographic Progression and Maintains
    Clinical Efficacy and Safety in Patients with Active Rheumatoid Arthritis
    Despite Methotrexate Therapy: 1-Year Results of a Phase 3 Trial
  oUstekinumab in Active Psoriatic Arthritis Including Patients Previously
    Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter,
    Double-blind, Placebo-controlled Study; Continued Improvement of Signs and
    Symptoms in Ustekinumab-treated Patients with Active Psoriatic Arthritis:
    Week 52 Results of a Phase 3, Multicenter, Double-blind,
    Placebo-controlled Study

The pre-recorded webcast with management from the Company's Janssen
pharmaceutical subsidiaries, will provide an update on the Immunology
rheumatology pipeline and commercial franchise.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website
at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

Website: http://www.investor.jnj.com
Contact: Press Contacts: Al Wasilewski, +1-732-524-1130 or Bill Price,
+1-732-524-6623; or Investor Contacts: Stan Panasewicz, +1-732-524-2524, or
Louise Mehrotra, +1-732-524-6491
 
Press spacebar to pause and continue. Press esc to stop.